Syndax Pharmaceuticals (SNDX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Stephen Willey.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stephen Willey has given his Buy rating due to a combination of factors related to Syndax Pharmaceuticals’ promising market position and growth potential. The recent commercial launches of two key assets, each with potential peak sales exceeding $1 billion, are pivotal to the company’s projected profitability by the second half of 2026. Willey highlights Revuforj’s competitive edge in the menin inhibitor class, particularly its first-mover advantage in treating specific leukemia patients, which is expected to drive significant near-term growth.
Additionally, the partnership with INCY for Niktimvo is seen as a high-margin opportunity, with potential for label expansion and long-term growth in various treatment areas. The strategic clinical development of Revuforj, targeting a broad spectrum of leukemia patients, positions it to capture a substantial share of the U.S. market, fundamentally changing the perception of the AML treatment landscape. These factors collectively underpin Willey’s optimistic outlook and Buy rating for Syndax Pharmaceuticals.
According to TipRanks, Willey is a 4-star analyst with an average return of 4.5% and a 41.74% success rate. Willey covers the Healthcare sector, focusing on stocks such as Celcuity, Incyte, and Insmed.
In another report released on September 8, Goldman Sachs also maintained a Buy rating on the stock with a $24.00 price target.